Immunology and autoimmune disease is the second largest therapeutic area in pharmaceuticals after oncology, generating revenues exceeding $150 billion annually. The post-Humira era is reshaping the competitive landscape more dramatically than any patent expiry in pharmaceutical history as the category simultaneously loses its largest single product and grows rapidly through the commercial success of next-generation biologics.
Sanofi’s Dupixent reached $18.5 billion in 2025 revenues. AbbVie’s Skyrizi reached $17.6 billion and Rinvoq $8.3 billion. J&J’s Tremfya is growing rapidly. These three portfolios collectively define the competitive frontier of modern immunology.
This report provides significant competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D programs.
Topics Covered
• Post-Humira Competitive Landscape
• IL-23 Inhibitors
• Dupixent and Type 2 Inflammation
• JAK Inhibitors
• Novel Immunology Targets
• Inflammatory Bowel Disease
• Rare Autoimmune Disease
Table of Contents
1. Executive Summary
2. Market Overview
3. IL-23 Inhibitors
4. Dupixent and Type 2 Inflammation
5. JAK Inhibitors
6. Novel Immunology Targets
7. Inflammatory Bowel Disease
8. Rare Autoimmune Disease
9. Competitive Landscape
10. Regional Market Analysis
11. Strategic Conclusions and Recommendations
12. Appendix
List of Tables
Table 1. Market Overview and Leading Products 2025
Table 2. Competitive Landscape by Sub-Segment 2025
Table 3-8. Topic-Specific Analysis Tables
Table 3. Leading Companies — Portfolio and Pipeline Assessment 2025
Table 4. M&A and Licensing Activity 2023-2025
Table 5. Regional Market Analysis
Table 6. Key Risks and Mitigation Strategies
Companies Profiled
AbbVie
Roche
Johnson & Johnson
Sanofi
Regeneron
UCB
Bristol-Myers Squibb
Novartis
Pfizer
